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In June 2012, 13 thought leaders convened in a Diabetes Care Editors’ Expert Forum to discuss
the concept of personalized medicine in the wake of a recently published American Diabetes
Association/European Association for the Study of Diabetes position statement calling for a
patient-centered approach to hyperglycemia management in type 2 diabetes. This article, an
outgrowth of that forum, offers a clinical translation of the underlying issues that need to be
considered for effectively personalizing diabetes care. The medical management of type 2 di-
abetes has become increasingly complex, and its complications remain a great burden to in-
dividual patients and the larger society. The burgeoning armamentarium of pharmacological
agents for hyperglycemia management should aid clinicians in providing early treatment to delay
or prevent these complications. However, trial evidence is limited for the optimal use of these
agents, especially in dual or triple combinations. In the distant future, genotyping and testing for
metabolomic markers may help us to better phenotype patients and predict their responses to
antihyperglycemic drugs. For now, a personalized (“n of 1”) approach in which drugs are tested
in a trial-and-error manner in each patient may be the most practical strategy for achieving
therapeutic targets. Patient-centered care and standardized algorithmic management are conflict-
ing approaches, but they can be made more compatible by recognizing instances in which
personalized A1C targets are warranted and clinical circumstances that may call for comanage-
ment by primary care and specialty clinicians.
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n April 2012, the American Diabetes
Association (ADA) and the European
Association for the Study of Diabe-
tes (EASD) published a joint position
statement titled “Management of Hyper-
glycemia in Type 2 Diabetes: A Patient-
CenteredApproach” (1). It was an important
update to earlier guidelines (2–8),
providing a thorough examination of the
ever-more-complex therapeutic options
for glycemic management, the benefits
and risks of tight glycemic control, the
efficacy and safety evidence for new
drug classes, and the data supporting
withdrawals of or restrictions on other
agents. Furthermore, it placed great em-
phasis on patient-centered and personal-
ized care.
These recommendations captured
the attention of theDiabetes Care editorial
team. On the one hand, the recommen-
dations call for a more personalized
approach, which, in theory, should be lib-
erating for all health care providers
(HCPs) involved in diabetes care. On
the other hand, their “less prescriptive”
nature has been viewed as providing in-
sufficient guidance to some HCPs who
may feel overwhelmed when trying to
match the nuances of differences among
the increasing number of antihyperglyce-
mic medications to the nuances of each
patient’s preferences and medical charac-
teristics.
To explore these issues, we con-
vened a Diabetes Care Editors’ Expert
Forum in June 2012. Thirteen thought
leaders from around the world convened
and discussed approaches to personalized
medicine, the rationale behind personali-
zation in diabetes care, the tools necessary
to implement such a strategy, and the cur-
rent perceptions of personalized medi-
cine. This narrative provides our view
and clinical translation of the underlying
issues that need to be considered for per-
sonalizing care and offers suggestions to
stimulate future research in this area.
Table 1 summarizes the main points dis-
cussed below.
PRACTICAL APPROACHES TO
PERSONALIZED MEDICINE
From intervention trials to
personalized targets
There can be little more than semantic
differences among the terms “personal-
ized medicine,” “patient-centered care,”
and “clinical judgment.” Factors such as
patients’ preferences, life expectancy,
disease duration, comorbid conditions,
socioeconomic status, and cognitive abil-
ities have long played a role in the selec-
tion of optimal therapeutic options and,
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more recently, in the selection of thera-
peutic targets.
In 1998, the UK Prospective Diabetes
Study (UKPDS) showed that treating
patients with recently diagnosed type 2
diabetes reduced the risk of microvascu-
lar, but not macrovascular, complications
(9). Of the three subsequent randomized
controlled trials (RCTs) on glucose lower-
ing and cardiovascular outcomes, two—
ADVANCE (Action inDiabetes andVascular
Disease: Preterax and Diamicron MR Con-
trolled Evaluation) and VADT (Veterans
Affairs Diabetes Trial)—showed no statisti-
cally significant reduction in cardiovascular
outcomes, while the glycemic intervention
of the third—ACCORD (Action to Control
Cardiovascular Risk in Diabetes)—was
ended early because of increased mortality
in participants randomized to intensive
glycemic control (10–12). However, meta-
analyses of the four intervention trials
(UKPDS, ACCORD, ADVANCE, and VADT)
have shownmodest but statistically signif-
icant benefit of intensive glucose control
on the risk for myocardial infarction, but
not mortality (13).
Post hoc analyses seeking explana-
tions for these results set the stage for
today’s new emphasis on personalized
care. Suggestions that adverse effects of
individual therapeutic agents or severe
hypoglycemia were directly implicated
in causing cardiovascular events were
not supported by these analyses but can-
not be ruled out because efforts to capture
hypoglycemic events were probably in-
adequate, especially in individuals with
hypoglycemia unawareness (13). How-
ever, individuals assigned to intensive
therapy who failed to improve control
to A1C levels ,7.0% (,53 mmol/mol)
in ACCORD fared poorly and had more
severe hypoglycemia, and severe hypo-
glycemia was noted to be a risk marker
for a wide range of medical conditions in
ADVANCE (14,15). It was also suggested
that individuals with long-standing type
2 diabetes, existing cardiovascular
disease (CVD), and other comorbidities
were unable to achieve cardiovascular
benefit from better glucose lowering
within the timeframe of these studies
(16).
Accordingly, these trials and their
subsequent analyses raised important
questions about rigid, algorithm-based,
“glucocentric” approaches to therapy.
One message, then, is that “one size
does not fit all” for glucose targets, choice
of therapy, or number of therapies used in
combination. However, some questions
pertinent to personalization remain unan-
swered. What were the characteristics of
the small group of individuals in
ACCORD who failed to respond to fur-
ther glucose-lowering therapy but who
contributed much of the excess case fatal-
ity (12)? Similarly, what can these studies
teach us about patients who benefitted
most from the interventions? Gaining in-
sight into the pathophysiological, genetic,
lifestyle, adherence, comorbidity, or
other factors responsible for these dispa-
rate responses could improve our ability
to effectively personalize therapy.
The 2012 ADA/EASD position state-
ment still recommends an A1C goal of
,7.0% (,53 mmol/mol) for most
individuals with type 2 diabetes if it can
be achieved safely in low-risk individuals
with early diabetes or a relatively long life
expectancy; it suggests an acceptance of
higher A1C targets for individuals with a
history of severe hypoglycemia, limited
life expectancy, long-standing diabetes,
or advanced micro- and macrovascular
complications (1). Prior guidelines from
multiple organizations (3–8) included
recommendations about setting person-
alized glycemic targets based on pheno-
type and empirically matching “the right
drugs to the right patients,” but without
hard evidence to substantiate such an
approach. Personalized treatment was
articulated more vigorously in the new
position statement (1).
The challenges of personalized care
Patient-centered personalized therapy,
although appealing, may be difficult to
implement without a good understanding
of the ever-changing glucose-lowering
armamentarium. b-Cell dysfunction is
progressive in type 2 diabetes (9), and
thus monotherapy, or even combinations
of oral agents, is not likely to control hy-
perglycemia indefinitely (17), although
the ORIGIN (Outcome Reduction With
Initial Glargine Intervention) trial demon-
strated sustained normoglycemia with
basal insulin glargine plus metformin
and near-normoglycemia even with stan-
dard therapy using metformin plus a sul-
fonylurea over a 6–7 year period in early
type 2 diabetes (18). At this time, the pro-
cesses of assessing b-cell function and
providing reliable clinical decisions
based on this factor are less than optimal.
Furthermore, so-called evidence-based
guidelines may be limited in their ability
to be more prescriptive given the lack of
clinical trial evidence from properly con-
ducted long-term RCTs comparing the
effects of various agents on clinically im-
portant outcomes. Clinical inertia is also a
problem, and most clinicians do not alter
their patients’ glucose-lowering regimens
until A1C is significantly elevated (19).
Developing and implementing personal-
ized care plans may be especially daunting
for those HCPs whose practice extends
beyond diabetes alone and who must ad-
dress these issues in the context of limited
time and resources.
The need for translational tools
The task now at hand is clear: We should
develop and make available tools that will
enable effective translation of existing
guidelines on targets and therapeutic op-
tions into practical clinical applications.
Table 1—Summary of the main points from
the Diabetes Care Editors’ Expert Forum
c The complexity of management of type 2
diabetes is underappreciated.
c Its complications, once established, remain
a largely intractable burden.
c The number of available antihyperglycemic
agents has increased markedly during the
past 2 decades, but trial evidence for their
optimal use—especially in dual or triple
combinations—is limited and unlikely to
ever be complete.
c The availability of multiple pharmacological
options should be instrumental to early,
appropriate treatment to target, which is the
only recognized strategy for the prevention of
complications.
c In the more distant future, genotyping and
testing for metabolomic markers may help to
phenotype patients and predict their
responses to antihyperglycemic drugs.
c At present, a personalized (“n of 1”) approach
may aid in achieving therapeutic targets.
c Patient-centered care and standardized,
algorithmic management are conflicting
approaches, but they can be made more
compatible by recognizing instances in
which personalized A1C targets are
warranted and clinical circumstances that
may call for primary care and specialty
comanagement.
c Failure to achieve glycemic targets, failure to
respond to therapy, recurrent hypoglycemia,
drug intolerances/contraindications, the
development of complications, hyperglycemia
during hospitalization, pregnancy, and
suspicion of unusual variants such as MODY,
LADA, heavy proteinuria with short disease
duration in the absence of other microvascular
complications, or secondary diabetes all may
serve as triggers for comanagement.
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It is one thing to assess the efficacy of an
intervention within the context of a struc-
tured clinical trial setting, but entirely
different to evaluate that intervention in
ordinary clinical practices with resource
variations, variable patient adherence, and
sociodemographic and cultural differen-
ces. Thus, the translation of results from
RCTs to real-world situations is not an
exact science. Until more hard evidence
becomes available, clinicians need well-
structured and user-friendly evidence
summaries that outline safe and effective
processes for therapeutic intensification,
while still allowing for the personalization
of care.
Although such an undertaking is
beyond the scope of this discussion, we
are providing a starting point that may
guide the development of such tools to
aid HCPs in personalizing both targets
and therapeutic regimens. For target-
setting, suggestions have been made in
the past (20,21). Another possible start-
ing place might be the decision-making
scale developed by Ismail-Beigi et al.
(22) and adapted for inclusion in the
ADA/EASD position statement (1). That
scale includes seven parameters to con-
sider when determining glycemic targets.
Expanding it or providing some means
of rating each parameter for individual
patients could help clinicians to better
weigh factors such as life expectancy,
duration of diabetes, risk from hypogly-
cemia, comorbidities, and availability
of support systems. Such a tool could
assist clinicians in choosing targets and
help to involve patients in the decision-
making process in an easily understood
manner.
Tools are also needed to help HCPs in
selecting appropriate agents and intensi-
fying therapy. The ADA/EASD position
statement leaves treatment-goal decisions
to clinicians and patients (1). However,
some believe that because of the vast
and expanding array of available drugs,
there should be a systematic way to pri-
oritize the selection of drugs in relation to
their efficacy, safety, and cost. It is most
important to emphasize that the percent-
age of patients who show sufficient clini-
cal response to any of these drugs varies
widely. Nonadherence to treatment regi-
mens may be as high as 50% in patients
with chronic diseases such as diabetes
(23), often because of the patients’ lack
of symptoms, negative emotions, and
poor knowledge of their disease (24).
Side effects are another cause of stopping
or limiting treatment. Thus, patients must
be adequately monitored, especially after
changes to their treatment regimen, to
evaluate whether they have reached tar-
gets and to ensure that there are no ma-
jor side effects or adherence issues. This
information is crucial to make informed
decisions regarding whether to continue,
change, or add to the therapy regimen.
STATE OF THE ART FOR
PERSONALIZING MEDICINE—
Personalized medicine can be defined in
many ways. A shared decision-making
approach that takes patient preferences
and values into account in developing a
management plan is widely endorsed.
Another definition involves identifying a
particular set of phenotypic and geno-
typic markers that would define ideal and
nonideal therapies for individuals based,
to whatever extent possible, on evidence
rather than on clinical impressions. Per-
haps the most relevant question is
whether current science is at a stage where
specific patient characteristics—genetic,
pathophysiological, or phenotypic—
might effectively guide us in more general
diabetes practice.
Contributions from genetics: a
distant hope
The field of genetics is not yet ready to
contribute in these broader areas. Despite
recent identification of monogenic forms
of diabetes for which specific treatments
seem to give benefit (25), for more typical
type 2 diabetes, genetic information does
not contribute greatly in guiding treat-
ment choices. Recently, pharmacogenetic
analysis has begun providing insights,
finding possible links, for example, to
poor responses to metformin (26,27)
and glucagon-like peptide-1 (GLP-1) re-
ceptor agonists (28–30). Such research
holds promise for eventually helping to
identify individuals who are likely to be
classified as “responders” or “nonres-
ponders” to specific agents.
Human genome sequencing also of-
fers some hope, but again, in the distant
future (31). Because the development of
diabetes, patients’ responses to available
therapies, and the risks for complications
are all multifactorial and probably involve
numerous genes, the chances are small
that specific mutations will turn out to
be powerful markers of diabetes risk or of
variable treatment responses. Even assum-
ing a significant increase inpharmacogenetics
research and decreases in the costs asso-
ciated with genome sequencing, for the
foreseeable future these efforts will not
significantly improve our ability to predict,
prevent, or diagnose diabetes or illuminate
definitive pathways for selecting drug ther-
apies for specific individuals.
What can we learn from
pathophysiology?
Insulin resistance in the liver and muscle
and islet b-cell failure represent the core
pathophysiological defects in type 2 di-
abetes (32,33). Insulin resistance can of-
ten be demonstrated long before the
onset of b-cell failure, but as long as the
b-cells secrete sufficient amounts of in-
sulin to offset the insulin resistance, glu-
cose tolerance remains normal (32–36).
With time, however, there is progressive
b-cell failure, which leads to the develop-
ment of impaired glucose tolerance and/
or impaired fasting glucose and eventu-
ally type 2 diabetes (32–36). As the
plasma insulin response declines, insulin
resistance in the liver becomes manifest
as an overproduction of glucose by the
liver and the development of fasting hy-
perglycemia, while insulin resistance in
muscle results in diminished glucose up-
take and postprandial hyperglycemia
(32,33).
Although the relative contributions of
b-cell failure (possibly more severe in
Asian populations) and insulin resistance
(more severe in Westernized societies
with a high prevalence of obesity) may
vary among different ethnic groups (37),
virtually all adults with type 2 diabetes
have some combination of the two.
Thus, antihyperglycemic agents that im-
prove b-cell function and enhance he-
patic and muscle insulin sensitivity may
have a more durable effect in reducing
A1C (38–45).
The importance of other pathophys-
iological disturbances in the development
of type 2 diabetes is well recognized
(32,33). These disturbances include
c Adipocyte insulin resistance, which
leads to increased lipolysis, increased
plasma free fatty acids, and eventual
b-cell failure and muscle and hepatic
insulin resistance (46)
c Excess glucagon secretion by a-cells
and enhanced hepatic sensitivity to
glucagon, leading to increased basal
hepatic glucose production and im-
paired suppression of hepatic glucose
production after meals (47,48)
c Dysfunction related to incretin hor-
mones (GLP-1 and glucose-dependent
insulinotropic peptide) (49), which are
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responsible for ;50% of the insulin
secreted in response to meals
c Possible renal adaptive mechanisms
to hyperglycemia, which result in en-
hanced glucose reuptake leading to
decreased urinary glucose clearance
and the maintenance of established
hyperglycemia (50)
c Central nervous system insensitivity to
the anorectic effect of insulin and mul-
tiple neurotransmitter synaptic abnor-
malities resulting in excessive energy
intake and obesity (33)
No single antihyperglycemic agent
can correct all of these pathophysiological
abnormalities. Thus, many patients may
require multiple agents with different
mechanisms of action to achieve their
individualized A1C goal (33). Patients
with type 2 diabetes who have a high ini-
tial A1C, in particular, may require two or
more antihyperglycemic agents to achieve
their A1C goal (1,4,7,8,33,51,52).
The precise choice of pharmacologi-
cal agents to use remains a topic for
debate, in part because of safety concerns
involving several drug classes (53–55).
But the basic point remains: To achieve
durability of glycemic control, optimal
regimens will likely need to address
both insulin resistance and b-cell failure.
Does phenotype allow for
personalized treatment?
The main characteristics that might in-
fluence approaches to treatment can be
divided into two categories: patient fea-
tures and disease features. Among the
patient features are race/ethnicity, sex, age
of onset or diagnosis, duration of diabetes,
body weight, frailty/comorbidities, compli-
cations, propensity for side effects/drug
tolerance, personality and aspirations, and
psychosocial-economic context. Among
the disease features are the balance between
insulin deficiency and insulin insensitivity,
fasting versus postprandial hyperglycemia,
short versus long disease duration, and
special circumstances such as maturity-
onset diabetes of the young (MODY) or
latent autoimmune diabetes in adulthood
(LADA).
However, we are faced with a paucity
of data on how patients with certain
characteristics respond to specific thera-
pies (56). We know that most glucose-
lowering drugs for type 2 diabetes work
in most patients. But we also know that
there are nonresponders to any drug. Nu-
merous post hoc studies have revealed
some predictors of better responses, but
the data are inconclusive (57–60). Fur-
thermore, those response differences
tend to be small, and the strongest pre-
dictor remains baseline A1C, with the pa-
tients with higher A1C levels responding
with greater reductions although not nec-
essarily attaining target levels (58,61).
Indeed, the most fruitful phenotypic
considerations for personalizing care to-
day may be patients’ propensity for side
effects and tolerance of various medi-
cines. There may be practical value to
using a trial-and-error, or “n of 1,” ap-
proach (62) based on the anticipation
of a drug’s efficacy (for example, “Piogli-
tazone will be highly effective in this very
insulin-resistant patient”), a patient’s
need for certain added benefits (“A GLP-1
receptor agonist will help control hy-
perglycemia and may encourage weight
loss in this obese patient”), and concerns
about adverse events (“I will not
prescribe a sulfonylurea for this elderly
patient who lives alone and had a severe
hypoglycemic episode a few years ago”).
This is becoming standard clinical proce-
dure for diabetes, just as it is for hy-
pertension and numerous other chronic
diseases.
The challenge is how to proceed in
more complex situations. How, for ex-
ample, would one select an appropriate
pharmacological regimen for a 68-year-
old man with diabetes of 14 years’ duration
who has coronary disease, obstructive
sleep apnea, prostate cancer, and a history
of possible pancreatitis; who is obese and
has edema but no heart failure; who
smokes and has a family history of bladder
cancer; who has high fasting blood glu-
cose and A1C levels; and who has some
renal dysfunction and poorly controlled
lipids? With so many competing comor-
bidities, what are this individual’s targets
and treatment options?
Ultimately, clinicians must develop
highly personalized care regimens, and,
in the absence of other conclusive evi-
dence, “n of 1” trials may prove to be the
best approach, providing strong evidence
of therapy effectiveness and safety at the
individual level and incorporating shared
decision making with patients.
ARE ADEQUATE THERAPEUTIC
TOOLS AVAILABLE NOW FOR
PERSONALIZED DIABETES
CARE?
Multiple glucose-lowering medication
classes: freedom or confusion?
We now have numerous classes of anti-
hyperglycemic therapies (Table 2) and
more are expected to be licensed. Does
this extensive arsenal provide us with
more flexibility in designing personalized
diabetes regimens, or does it make the
task more difficult by multiplying the op-
tions? For specialists, the answer is no
doubt the former. But for many primary
care providers who must simultaneously
stay abreast of developments in numer-
ous fields of medicine, the expanding
array of choices may, at times, seem
intimidating.
Recent meta-analyses have shown
that there is not much difference among
available therapies in glycemic control
(e.g., A1C reduction and likelihood of
achieving targets when adding an agent to
metformin). However, when one consid-
ers other benefits, such as the risk of
hypoglycemia and effects on body weight
(63,64), there appears to be separation
among the agents. In addition to these
agents’ relative glycemic efficacy and ef-
fects on body weight and hypoglycemia,
HCPs immersed in diabetes caremust bal-
ance the potential benefits of each agent
against concerns that have been raised re-
garding possible associations between
various agents and the risk of developing
other diseases (65–67).
Difficulties in making benefit-risk
judgments are further amplified by the
fact that marketing may seek to create
demand for drugs that is out of proportion
to their efficacy. In addition, there
remains a general lack of adequate com-
parative and exploratory controlled trials
between the medications available, not to
mention a lack of research into phenotype-
and pathophysiology-based regimens.
Developing a straightforward algo-
rithm that narrows the field of viable
options will clearly require more evidence
Table 2—Classes of antihyperglycemic
agents
1. Insulins
2. Sulfonylureas
3. Metformin
4. a-Glucosidase inhibitors
5. Glinides
6. Pioglitazone
7. Pramlintide
8. GLP-1 receptor agonists
9. Dipeptidyl peptidase-4 inhibitors
10. Colesevelam
11. Bromocriptine
12. SGLT-2 inhibitors
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than is currently available. Without such
evidence, we can offer only opinion, albeit
opinion based on an understanding of
pathophysiology, epidemiology, pharma-
codynamics, toxicology, and costs. Un-
fortunately, the studies needed to make
evidence-based treatment decisions—
those that involve comparisons among
multiple agents and are adequately pow-
ered for important, long-term clinical
outcomes—have, for the most part, not
been performed.
The upcoming GRADE (Glycemia
Reduction Approaches in Diabetes:
A Comparative Effectiveness Study) trial
will address some of these points (68). In
addition, studies on how best to combine
the various agents, as well as the optimal
timing (early combination therapy vs. the
traditional step-wise approach), are ur-
gently needed.
Furthermore, even the most carefully
considered set of guidelines is based on
averages—average A1C-lowering effect,
average efficacy, average risk of adverse
effects—without adequate consideration
of the confidence intervals around those
averages. Averages fail to identify subpo-
pulations that respond better and have
better tolerance to specific agents, and
without these data, evidence-based per-
sonalized advice cannot be provided.
For now, all HCPs, whether in specialty
or primary care settings, should test the
efficacy and weigh the safety risks of any
given drug in each patient, ideally trying
options over a period ofmonths to see how
well they work at the individual level.
How will new and emerging
therapies enhance our ability to
personalize care?
To complicate future decision making,
there are many new therapies in the
research and development pipeline, in-
cluding newer and longer-acting inject-
able incretin-based drugs, newer basal
insulins, oral sodium-glucose cotransporter-
2 (SGLT-2) inhibitors, agents targeting the
various peroxisome proliferator–activated
receptors, and free fatty acid receptor ago-
nists.
It is hoped that pharmaceutical com-
panies developing new glucose-lowering
agents will focus on providing some
added value beyond what is already avail-
able by addressing unmet clinical needs
such as the effects leading to a reduction
in CVD risk factors and meaningful
cardiovascular and other outcomes. Argu-
ably, we lack what we seek most in a di-
abetes treatment: definitive demonstration
that an agent can safely lower A1C in a
sustained and durable manner by defini-
tively modifying disease progression, does
so with minimal side effects (e.g., hypo-
glycemia), favorably improves CVD risk
factors (e.g., weight, lipids, and blood
pressure), and reduces cardiovascular
and other morbidity and mortality.
As new drugs continue to be de-
veloped and submitted to regulatory
agencies for approval, we should also
consider the limitations of RCTs for
informing a personalized approach to
diabetes care (69,70). RCTs, at least as
currently carried out, focus on selected
populations and have restricted inclusion
and exclusion criteria. They are generally
of short duration, making it impossible to
assess durability. They do not test indi-
vidual responder rates and are not de-
signed to identify responders who
have a low safety risk. These trials are
conducted in artificial environments,
which pose problems for realistically
measuring adherence. Finally, RCTs are
not powered to assess subpopulations
prospectively. Thus, efforts to personalize
therapy are hindered by our reliance on
trials that may be neither generalizable to
the larger population nor individualized
to specific patients.
Moving forward, there may be other
informative data from these trials, not
from the average results, but rather from
outliers—the results from subjects who
respond very well or not at all.
REGIONAL PERSPECTIVES ON
PERSONALIZEDMEDICINE—The
questions, concerns, and practical con-
siderations discussed here pose difficult
challenges for diabetes HCPs throughout
the world. Because diabetes is a burgeon-
ing pandemic, it behooves us to under-
stand the issues from an international
perspective.
The viewpoint that personalized di-
abetes care may be too complex to be
implemented in many care settings is
common in Europe, as it is in the United
States and elsewhere. In Italy, for exam-
ple, the Renal Insufficiency And Cardio-
vascular Events (RIACE) multicenter
study, which included 15,773 patients
with type 2 diabetes attending hospital-
based diabetes clinics, showed that 40%
of patients were taking metformin, 15%
weremanaged through diet only, 24%were
on insulin, 18% were taking sulfonylureas,
and 3% were taking thiazolidinediones
(71). Strikingly, this pattern did not
change with age or with renal function,
duration of disease, or other stratifying
criteria.
The story is much the same in other
parts of the world, although patient
characteristics differ. In China, key issues
include rapid nutritional and lifestyle
transitions, large patient populations,
young age of onset, and heterogeneous
phenotypes characterized by b-cell dys-
function, insulin resistance, and visceral
obesity (72,73). High rates of kidney dis-
ease and diabetes-related cancer compli-
cate diabetes care (72,74,75). All of these
problems are compounded by a relative
scarcity of research, low levels of aware-
ness, an insufficient number of trained
HCPs, and less-organized health care
and financing systems.
Given the large population and finite
resources, one may argue for using risk
algorithms and biomarkers, including ge-
netic variants, to identify high-risk subjects
for early or intensified intervention, al-
though the cost-effectiveness of such an
approachwill need to be formally tested. As
elsewhere, patients with insulin-resistant
features such as fatty liver, high triglycer-
ides, and low HDL cholesterol may benefit
from initial treatment with metformin,
pioglitazone, and GLP-1 receptor agonists,
whereas patients who are lean and face a
long disease duration may benefit from
dipeptidyl peptidase-4 (DPP-4) inhibitors
or sulfonylureas with the early use of
insulin. Other drugs such as a-glucosidase
inhibitors and SGLT-2 inhibitors may help
to lower A1C with a low risk of hypoglyce-
mia and weight gain.
Although these phenotype-based
therapies have a theoretical basis, clinical
practice studies are needed to confirm
their cost-effectiveness. There is also a
need to empower medical and nonmed-
ical personnel (diabetes educators) in
clinics to collect patient data on demo-
graphics, risk factors, complications, so-
cial habits, emotional needs, self-care
behaviors, compliance, expectations,
and values to enable HCPs to personalize
treatment goals, self-management strate-
gies, and therapy regimens (76). These
personnel should monitor patients’ ad-
herence to treatment, as well as their
achievement of treatment goals.
In the United States, attempts to im-
plement a concept as expansive as per-
sonalized care quickly run up against two
opposing traditions that permeate not
only the field of medicine, but indeed
the entire U.S. culture. The first, rooted in
American industrialism, is standardization,
exemplified by the processes of production
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line efficiency and continuous quality
improvement. One recognizes this tradi-
tion in the vision of industrialist Henry J.
Kaiser, who founded the prototype non-
profit health system Kaiser Permanente
(77). The second tradition, embodied by
the image of artist Norman Rockwell’s
humble country doctor, is personalization.
This is apparent in the teachings of
Dr. Francis W. Peabody, whose seminal
dissertation on patient care concluded,
“The secret of care of the patient is caring
for the patient,” (78) and in the work of Dr.
Elliott P. Joslin, who wrote that “ . . . unless
the physician takes care, he will fall into
schematic ways and forget that it is the pa-
tient who comes for treatment and not the
diabetes. Each is a case unto itself” (79).
Recent guidelines for diabetes care in
the United States have fallen somewhere
along a continuum between these tradi-
tions. The ADA Standards of Care (80)
have sought to straddle the line, whereas
the algorithm-based 2009 ADA/EASD
consensus statement (2) leaned more to-
ward standardization, and the 2012 ADA/
EASD position statement (1) evolved
more toward personalized care.
ENHANCING PERSONALIZED
CARE THROUGH
COMANAGEMENT—Research has
yielded strong evidence in favor of fairly
standardized treatment goals and an al-
gorithmic initial therapy pathway involv-
ing lifestyle modification, metformin, and
the eventual addition of other oral agents
(sulfonylureas and basal insulin, in most
cases). This approach allows many newly
diagnosed patients to attain a reasonable
blood glucose range and to maintain it for
some period of time.
However, there will always be pa-
tients for whom the standard A1C target is
not appropriate (Fig. 1). Likewise, pa-
tients’ clinical circumstances often be-
come more complicated over time, at
which point the core treatment algorithm
must give way to a more personalized ap-
proach. In such situations, the ideal course
of action would be a patient-centered
comanagement approach involving pri-
mary and specialty care providers as
well as diabetes educators, dietitians, psy-
chologists, and other HCPs as warranted
by individual patient needs. Figure 2 de-
picts such an approach, which could be
invoked by specific triggers such as failure
to respond to treatment (14,81), failure to
attain A1C targets, drug intolerances or
contraindications, severe hypoglycemia,
hyperglycemia during hospitalization,
pregnancy, suspicion of unusual variants
such as LADA, MODY, or secondary di-
abetes, heavy proteinuria with short
disease duration in the absence of other
microvascular complications, or other
complicating circumstances.
Regardless of the final form such a pro-
cess takes, it seems clear that personalizing
diabetes care will require improved co-
operation and comanagement of patients
among HCPs in various disciplines. In
such a paradigm, algorithmic care would
be both a useful starting place for most
patients with type 2 diabetes and a frame-
work onwhich to buildmore personalized
therapy as needed.
CONCLUSIONS—Publication of the
latest ADA/EASD position statement on
type 2 diabetes management has generated
strong interest in the concept of a person-
alized medical approach for individuals
with diabetes (1). However, there are a
multitude of pharmacological antihypergly-
cemic therapies now available, often with
incomplete evidence concerning their
long-term efficacy, effectiveness, tolerabil-
ity, and safety. Accordingly, questions re-
main regarding the best ways to implement
the recommendations of the position state-
ment in the care of patients.
Emerging research in genetics, path-
ophysiology, metabolomics, and human
behavior, as well as longer-term, random-
ized comparative trials could eventually
yield new information to inform the
personalization of care. In the meantime,
we must develop tools to translate exist-
ing guidelines into practical clinical
applications, and, more importantly, to
develop processes that encourage the
organized comanagement of patients by
primary care providers, specialists, edu-
cators, dietitians, and other diabetes
HCPs as patients’ unique needs and risks
require. Another consideration is how
well the tools we develop can be imple-
mented around the globe given the differ-
ences in pathophysiology among ethnic
Figure 1—Personalizing A1C targets for individuals with type 2 diabetes.
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groups, country-specific resources and
medical care infrastructure, training level
of providers, and knowledge of patients.
We hope these reflections have
provided a broad overview of the evi-
dence deficits and procedural challenges
that will need to be overcome to ensure
success in our efforts to implement effec-
tive, personalized therapy regimens for
patients with type 2 diabetes.
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